Swiss National Bank’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.07M | Buy |
169,700
+8,200
| +5% | +$432K | ﹤0.01% | 1078 |
|
|
2025
Q4 | $8.47M | Buy |
161,500
+2,400
| +2% | +$144K | 0.01% | 1063 |
|
|
2025
Q3 | $10.3M | Buy |
159,100
+2,700
| +2% | +$155K | 0.01% | 951 |
|
|
2025
Q2 | $7.61M | Sell |
156,400
-700
| -0.4% | -$27.1K | ﹤0.01% | 1063 |
|
|
2025
Q1 | $5.35M | Sell |
157,100
-2,000
| -1% | -$84.8K | ﹤0.01% | 1222 |
|
|
2024
Q4 | $6.26M | Buy |
159,100
+1,500
| +1% | +$70.8K | ﹤0.01% | 1189 |
|
|
2024
Q3 | $7.4M | Sell |
157,600
-1,100
| -0.7% | -$55.8K | ﹤0.01% | 1090 |
|
|
2024
Q2 | $8.57M | Buy |
158,700
+9,800
| +7% | +$567K | 0.01% | 972 |
|
|
2024
Q1 | $10.1M | Buy |
148,900
+200
| +0.1% | +$14.3K | 0.01% | 901 |
|
|
2023
Q4 | $9.31M | Sell |
148,700
-16,100
| -10% | -$890K | 0.01% | 920 |
|
|
2023
Q3 | $7.48M | Buy |
164,800
+2,100
| +1% | +$108K | 0.01% | 1042 |
|
|
2023
Q2 | $9.13M | Buy |
162,700
+2,200
| +1% | +$125K | 0.01% | 957 |
|
|
2023
Q1 | $7.26M | Sell |
160,500
-18,500
| -10% | -$899K | 0.01% | 1050 |
|
|
2022
Q4 | $7.28M | Buy |
179,000
+4,500
| +3% | +$239K | 0.01% | 1087 |
|
|
2022
Q3 | $11.4M | Buy |
174,500
+1,700
| +1% | +$123K | 0.01% | 820 |
|
|
2022
Q2 | $10.5M | Buy |
172,800
+28,100
| +19% | +$1.65M | 0.01% | 890 |
|
|
2022
Q1 | $9.08M | Buy |
144,700
+10,700
| +8% | +$672K | 0.01% | 1081 |
|
|
2021
Q4 | $10.2M | Hold |
134,000
| – | – | 0.01% | 1004 |
|
|
2021
Q3 | $15M | Buy |
134,000
+1,000
| +0.8% | +$126K | 0.01% | 785 |
|
|
2021
Q2 | $21.5M | Sell |
133,000
-2,100
| -2% | -$255K | 0.01% | 681 |
|
|
2021
Q1 | $16.5M | Buy |
135,100
+16,100
| +14% | +$2.43M | 0.01% | 750 |
|
|
2020
Q4 | $18.2M | Buy |
119,000
+2,700
| +2% | +$319K | 0.01% | 677 |
|
|
2020
Q3 | $9.73M | Buy |
116,300
+28,000
| +32% | +$2.48M | 0.01% | 815 |
|
|
2020
Q2 | $6.49M | Buy |
88,300
+30,000
| +51% | +$1.75M | 0.01% | 997 |
|
|
2020
Q1 | $2.47M | Buy |
58,300
+6,000
| +11% | +$310K | ﹤0.01% | 1323 |
|
|
2019
Q4 | $3.19M | Buy |
52,300
+2,800
| +6% | +$153K | ﹤0.01% | 1446 |
|
|
2019
Q3 | $2.03M | Buy |
49,500
+900
| +2% | +$43K | ﹤0.01% | 1646 |
|
|
2019
Q2 | $2.29M | Buy |
48,600
+10,800
| +29% | +$432K | ﹤0.01% | 1611 |
|
|
2019
Q1 | $1.35M | Buy |
37,800
+4,000
| +12% | +$138K | ﹤0.01% | 1895 |
|
|
2018
Q4 | $966K | Hold |
33,800
| – | – | ﹤0.01% | 2032 |
|
|
2018
Q3 | $1.5M | Buy |
33,800
+1,000
| +3% | +$52.4K | ﹤0.01% | 1887 |
|
|
2018
Q2 | $1.93M | Buy |
+32,800
| New | +$1.87M | ﹤0.01% | 1737 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
